We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Champions Oncology Inc | NASDAQ:CSBR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.16 | -3.27% | 4.74 | 4.74 | 4.94 | 4.89 | 4.60 | 4.89 | 3,906 | 21:30:00 |
|
|
|
|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13
OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
For the quarterly period ended October 31, 2017
|
¨
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
For the transition period from
to
|
Delaware
|
52-1401755
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
|
One University Plaza, Suite 307
|
07601
|
Hackensack, New Jersey
|
(Zip Code)
|
(Address of principal executive offices)
|
|
|
|
|
|
|
|
|
|
Item 1.
|
|
|
|
||
|
||
|
||
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
|
|
|
|
|
|
Item 1.
|
||
Item 1A.
|
||
Item 2.
|
||
Item 3.
|
||
Item 4.
|
||
Item 5.
|
||
Item 6.
|
|
October 31,
2017 |
|
April 30,
2017 |
||||
|
(unaudited)
|
|
|
||||
ASSETS
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
||
Cash and cash equivalents
|
$
|
660
|
|
|
$
|
3,295
|
|
Accounts receivable, net
|
2,578
|
|
|
2,274
|
|
||
Prepaid expenses and other current assets
|
303
|
|
|
300
|
|
||
|
|
|
|
||||
Total current assets
|
3,541
|
|
|
5,869
|
|
||
|
|
|
|
||||
Restricted cash
|
150
|
|
|
150
|
|
||
Property and equipment, net
|
2,026
|
|
|
1,216
|
|
||
Other Long Term Assets
|
107
|
|
|
107
|
|
||
Goodwill
|
669
|
|
|
669
|
|
||
|
|
|
|
||||
Total assets
|
$
|
6,493
|
|
|
$
|
8,011
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||
|
|
|
|
||||
Current liabilities:
|
|
|
|
|
|
||
Accounts payable
|
$
|
1,549
|
|
|
$
|
1,852
|
|
Accrued liabilities
|
390
|
|
|
685
|
|
||
Deferred revenue
|
3,879
|
|
|
4,910
|
|
||
|
|
|
|
||||
Total current liabilities
|
5,818
|
|
|
7,447
|
|
||
|
|
|
|
||||
Other non-current liabilities
|
302
|
|
|
164
|
|
||
|
|
|
|
||||
Total liabilities
|
6,120
|
|
|
7,611
|
|
||
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
|
|
||
Common stock, $.001 par value; 200,000,000 shares authorized; 11,265,175 and 11,251,844 shares issued and 10,988,347 and 10,982,159 shares outstanding as of October 31, 2017 and April 30, 2017, respectively
|
11
|
|
|
11
|
|
||
Treasury stock, at cost, 269,685 common shares as of October 31, 2017 and April 30, 2017
|
(1,252
|
)
|
|
(1,252
|
)
|
||
Additional paid-in capital
|
71,732
|
|
|
70,991
|
|
||
Accumulated deficit
|
(70,118
|
)
|
|
(69,350
|
)
|
||
|
|
|
|
||||
Total stockholders’ equity
|
373
|
|
|
400
|
|
||
|
|
|
|
||||
Total liabilities and stockholders’ equity
|
$
|
6,493
|
|
|
$
|
8,011
|
|
|
Three Months Ended
October 31, |
|
Six Months Ended
October 31, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Operating revenue:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Personalized oncology solutions
|
$
|
378
|
|
|
$
|
497
|
|
|
$
|
818
|
|
|
$
|
1,007
|
|
Translational oncology solutions
|
4,825
|
|
|
3,960
|
|
|
9,419
|
|
|
7,119
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total operating revenue
|
5,203
|
|
|
4,457
|
|
|
10,237
|
|
|
8,126
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Costs and operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cost of personalized oncology solutions
|
259
|
|
|
374
|
|
|
646
|
|
|
847
|
|
||||
Cost of translational oncology solutions
|
2,394
|
|
|
1,829
|
|
|
4,648
|
|
|
3,879
|
|
||||
Research and development
|
1,115
|
|
|
1,008
|
|
|
2,233
|
|
|
2,219
|
|
||||
Sales and marketing
|
551
|
|
|
717
|
|
|
1,235
|
|
|
1,643
|
|
||||
General and administrative
|
954
|
|
|
1,022
|
|
|
2,164
|
|
|
2,555
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Total costs and operating expenses
|
5,273
|
|
|
4,950
|
|
|
10,926
|
|
|
11,143
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Loss from operations
|
(70
|
)
|
|
(493
|
)
|
|
(689
|
)
|
|
(3,017
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Other (expense):
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other (expense)
|
(13
|
)
|
|
(16
|
)
|
|
(64
|
)
|
|
(25
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Total other (expense)
|
(13
|
)
|
|
(16
|
)
|
|
(64
|
)
|
|
(25
|
)
|
||||
|
|
|
|
|
|
|
|
||||||||
Loss before provision for income taxes
|
(83
|
)
|
|
(509
|
)
|
|
(753
|
)
|
|
(3,042
|
)
|
||||
Provision for (Benefit from) income taxes
|
11
|
|
|
(5
|
)
|
|
15
|
|
|
9
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Net loss
|
$
|
(94
|
)
|
|
$
|
(504
|
)
|
|
$
|
(768
|
)
|
|
$
|
(3,051
|
)
|
|
|
|
|
|
|
|
|
||||||||
Net loss per common share outstanding
|
|
|
|
|
|
|
|
|
|
|
|
||||
basic and diluted
|
$
|
(0.01
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.32
|
)
|
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
||||
basic and diluted
|
10,988,321
|
|
|
10,967,491
|
|
|
10,984,703
|
|
|
9,560,088
|
|
|
Six Months Ended
October 31, |
||||||
|
2017
|
|
2016
|
||||
Operating activities:
|
|
|
|
|
|
||
Net loss
|
$
|
(768
|
)
|
|
$
|
(3,051
|
)
|
|
|
|
|
||||
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
||
Stock-based compensation expense
|
711
|
|
|
1,664
|
|
||
Depreciation expense
|
132
|
|
|
87
|
|
||
Reversal of allowance for doubtful accounts
|
(41
|
)
|
|
(2
|
)
|
||
Issuance of common stock for services
|
30
|
|
|
15
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
||
Accounts receivable
|
(263
|
)
|
|
(577
|
)
|
||
Prepaid expenses and other current assets
|
(3
|
)
|
|
(3
|
)
|
||
Accounts payable
|
(303
|
)
|
|
(744
|
)
|
||
Accrued liabilities
|
(295
|
)
|
|
31
|
|
||
Other non-current liability
|
151
|
|
|
20
|
|
||
Deferred revenue
|
(1,031
|
)
|
|
5
|
|
||
|
|
|
|
||||
Net cash used in operating activities
|
(1,680
|
)
|
|
(2,555
|
)
|
||
|
|
|
|
||||
Investing activities:
|
|
|
|
|
|
||
Purchase of property and equipment
|
(942
|
)
|
|
(30
|
)
|
||
|
|
|
|
||||
Net cash used in investing activities
|
(942
|
)
|
|
(30
|
)
|
||
|
|
|
|
||||
Financing activities:
|
|
|
|
|
|
||
Proceeds from June 2016 Public Offering, net of financing costs of $742
|
—
|
|
|
4,340
|
|
||
Capital lease payments
|
(13
|
)
|
|
(12
|
)
|
||
|
|
|
|
||||
Net cash (used in)/provided by financing activities
|
(13
|
)
|
|
4,328
|
|
||
|
|
|
|
||||
(Decrease)/Increase in cash and cash equivalents.
|
(2,635
|
)
|
|
1,743
|
|
||
Cash and cash equivalents, beginning of period
|
3,295
|
|
|
2,585
|
|
||
|
|
|
|
||||
Cash and cash equivalents, end of period
|
$
|
660
|
|
|
$
|
4,328
|
|
|
Three Months Ended
October 31, |
|
Six Months Ended
October 31, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Basic and diluted net loss per share computation:
|
|
|
|
|
|
|
|
|
|
||||||
Net loss attributable to common stockholders
|
$
|
(94,318
|
)
|
|
$
|
(504,000
|
)
|
|
$
|
(768,475
|
)
|
|
$
|
(3,051,000
|
)
|
Weighted Average common shares – basic
|
10,988,321
|
|
|
10,967,491
|
|
|
10,984,703
|
|
|
9,560,088
|
|
||||
Basic and diluted net loss per share
|
$
|
(0.01
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.32
|
)
|
•
|
An allocation or shift of income between taxing jurisdictions;
|
•
|
The characterization of income or a decision to exclude reportable taxable income in a tax return; or
|
•
|
A decision to classify a transaction, entity or other position in a tax return as tax exempt.
|
|
October 31,
2017 |
|
April 30,
2017 |
||||
|
(unaudited)
|
|
|
||||
Furniture and fixtures
|
$
|
73
|
|
|
$
|
74
|
|
Computer equipment and software
|
956
|
|
|
872
|
|
||
Laboratory equipment
|
2,232
|
|
|
918
|
|
||
Assets in progress
|
19
|
|
|
472
|
|
||
Leasehold improvements
|
—
|
|
|
2
|
|
||
|
|
|
|
||||
Total property and equipment
|
3,280
|
|
|
2,338
|
|
||
Less: Accumulated depreciation
|
(1,254
|
)
|
|
(1,122
|
)
|
||
|
|
|
|
||||
Property and equipment, net
|
$
|
2,026
|
|
|
$
|
1,216
|
|
For the Years Ended April 30,
|
Total
|
||
2018 (remaining)
|
$
|
14
|
|
2019
|
28
|
|
|
2020
|
16
|
|
|
|
|
|
|
Total minimum payments
|
58
|
|
|
Less: amount representing interest
|
(3
|
)
|
|
Present value of minimum payments
|
55
|
|
|
Less: current portion
|
(26
|
)
|
|
|
$
|
29
|
|
|
Three Months Ended
October 31, |
|
Six Months Ended
October 31, |
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
General and administrative
|
$
|
96
|
|
|
$
|
469
|
|
|
$
|
519
|
|
|
$
|
1,298
|
|
Sales and marketing
|
7
|
|
|
18
|
|
|
41
|
|
|
187
|
|
||||
Research and development
|
42
|
|
|
45
|
|
|
122
|
|
|
130
|
|
||||
TOS cost of sales
|
3
|
|
|
3
|
|
|
28
|
|
|
47
|
|
||||
POS cost of sales
|
—
|
|
|
—
|
|
|
1
|
|
|
2
|
|
||||
Total stock-based compensation expense
|
$
|
148
|
|
|
$
|
535
|
|
|
$
|
711
|
|
|
$
|
1,664
|
|
|
Three Months Ended
October 31, |
|
Six Months Ended
October 31, |
||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Expected term in years
|
6
|
|
6
|
|
6
|
|
2.6 - 6
|
Risk-free interest rates
|
1.98%
|
|
1.48%
|
|
1.98%
|
|
0.75% - 1.48%
|
Volatility
|
87.1%
|
|
87.32%
|
|
87.1%
|
|
73.2% - 95.6%
|
Dividend yield
|
—%
|
|
—%
|
|
—%
|
|
—%
|
|
Non-
Employees
|
|
Directors
and
Employees
|
|
Total
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|
Aggregate
Intrinsic
Value
|
|||||||
Outstanding, May 1, 2017
|
50,000
|
|
|
2,258,704
|
|
|
2,308,704
|
|
|
$
|
2.86
|
|
|
6.1
|
|
$
|
1,282,000
|
|
Granted
|
—
|
|
|
194,977
|
|
|
194,977
|
|
|
2.51
|
|
|
9.7
|
|
|
|
||
Exercised
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
||
Forfeited
|
—
|
|
|
(6,042
|
)
|
|
(6,042
|
)
|
|
7.58
|
|
|
|
|
|
|
||
Canceled
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|||
Expired
|
—
|
|
|
(2,709
|
)
|
|
(2,709
|
)
|
|
8.44
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Outstanding, October 31, 2017
|
50,000
|
|
|
2,444,930
|
|
|
2,494,930
|
|
|
2.82
|
|
|
5.9
|
|
$
|
2,512,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Vested and expected to vest as of October 31, 2017
|
50,000
|
|
|
2,444,930
|
|
|
2,494,930
|
|
|
2.82
|
|
|
5.9
|
|
$
|
2,512,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Exercisable as of October 31, 2017
|
33,336
|
|
|
2,391,889
|
|
|
2,425,225
|
|
|
2.81
|
|
|
5.9
|
|
$
|
2,484,000
|
|
|
Number
of
Shares
|
|
Weighted
Average
Exercise
Price
|
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|
Aggregate
Intrinsic
Value
|
||||||
Outstanding, May 1, 2017
|
2,004,284
|
|
|
$
|
5.57
|
|
|
2.8
|
|
|
$
|
—
|
|
Granted
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
Exercised
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
Expired
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||
|
|
|
|
|
|
|
|
||||||
Outstanding, October 31, 2017
|
2,004,284
|
|
|
$
|
5.57
|
|
|
2.3
|
|
|
$
|
—
|
|
•
|
One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in
November 2021
. The Company recognized
$45,000
and
$43,000
of rental costs relative to this lease for the
six months ended October 31, 2017
and
2016
, respectively.
|
•
|
855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings. This lease expires
December 2017
. The Company recognized
$58,000
and
$52,000
of rental costs relative to this lease for the
six months ended October 31, 2017
and
2016
, respectively.
|
•
|
450 East 29t
h
Street, New York, New York, 10016, which is a laboratory facility. The Company recognized
$52,000
and
$103,000
of rental expense for the
six months ended October 31, 2017
and
2016
, respectively. The lease expired in
May 2017
and was not renewed.
|
•
|
1330 Piccard Drive, Suite 025, Rockville, MD 20850, which consists of laboratory and office space where the Company will conduct operations related to its primary service offerings. The Company executed this lease on January 11, 2017. The operating commencement date was August 11, 2017. This lease expires in
August 2028
. The Company recognized
$151,000
and
nil
of rental expense for the
six months ended October 31, 2017
and
2016
, respectively.
|
Three months ended October 31, 2017
|
|
Personalized
Oncology
Solutions
(POS)
|
|
Translational
Oncology
Solutions
(TOS)
|
|
Unallocated
Corporate
Overhead
|
|
Consolidated
|
||||||||
Net revenue
|
|
$
|
378
|
|
|
$
|
4,825
|
|
|
$
|
—
|
|
|
$
|
5,203
|
|
Direct cost of services
|
|
(259
|
)
|
|
(2,392
|
)
|
|
—
|
|
|
(2,651
|
)
|
||||
Sales and marketing costs
|
|
(85
|
)
|
|
(459
|
)
|
|
—
|
|
|
(544
|
)
|
||||
Other operating expenses
|
|
—
|
|
|
(1,073
|
)
|
|
(857
|
)
|
|
(1,930
|
)
|
||||
Stock- based compensation expense (1)
|
|
—
|
|
|
—
|
|
|
(148
|
)
|
|
(148
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Segment profit (loss)
|
|
$
|
34
|
|
|
$
|
901
|
|
|
$
|
(1,005
|
)
|
|
$
|
(70
|
)
|
Three months ended October 31, 2016
|
|
Personalized
Oncology
Solutions
(POS)
|
|
Translational
Oncology
Solutions
(TOS)
|
|
Unallocated
Corporate
Overhead
|
|
Consolidated
|
||||||||
Net revenue
|
|
$
|
497
|
|
|
$
|
3,960
|
|
|
$
|
—
|
|
|
$
|
4,457
|
|
Direct cost of services
|
|
(374
|
)
|
|
(1,826
|
)
|
|
—
|
|
|
(2,200
|
)
|
||||
Sales and marketing costs
|
|
(128
|
)
|
|
(571
|
)
|
|
—
|
|
|
(699
|
)
|
||||
Other operating expenses
|
|
—
|
|
|
(964
|
)
|
|
(552
|
)
|
|
(1,516
|
)
|
||||
Stock- based compensation expense (1)
|
|
—
|
|
|
—
|
|
|
(535
|
)
|
|
(535
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Segment profit (loss)
|
|
$
|
(5
|
)
|
|
$
|
599
|
|
|
$
|
(1,087
|
)
|
|
$
|
(493
|
)
|
Six Months Ended October 31, 2017
|
|
Personalized
Oncology Solutions (POS) |
|
Translational
Oncology Solutions (TOS) |
|
Unallocated
Corporate Overhead |
|
Consolidated
|
||||||||
Net revenue
|
|
$
|
818
|
|
|
$
|
9,419
|
|
|
$
|
—
|
|
|
$
|
10,237
|
|
Direct cost of services
|
|
(645
|
)
|
|
(4,620
|
)
|
|
—
|
|
|
(5,265
|
)
|
||||
Sales and marketing costs
|
|
(171
|
)
|
|
(1,023
|
)
|
|
—
|
|
|
(1,194
|
)
|
||||
Other operating expenses
|
|
—
|
|
|
(2,111
|
)
|
|
(1,645
|
)
|
|
(3,756
|
)
|
||||
Stock- based compensation expense (1)
|
|
—
|
|
|
—
|
|
|
(711
|
)
|
|
(711
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Segment profit (loss)
|
|
$
|
2
|
|
|
$
|
1,665
|
|
|
$
|
(2,356
|
)
|
|
$
|
(689
|
)
|
Six Months Ended October 31, 2016
|
|
Personalized
Oncology Solutions (POS) |
|
Translational
Oncology Solutions (TOS) |
|
Unallocated
Corporate Overhead |
|
Consolidated
|
||||||||
Net revenue
|
|
$
|
1,007
|
|
|
$
|
7,119
|
|
|
$
|
—
|
|
|
$
|
8,126
|
|
Direct cost of services
|
|
(845
|
)
|
|
(3,832
|
)
|
|
—
|
|
|
(4,677
|
)
|
||||
Sales and marketing costs
|
|
(269
|
)
|
|
(1,187
|
)
|
|
—
|
|
|
(1,456
|
)
|
||||
Other operating expenses
|
|
—
|
|
|
(2,090
|
)
|
|
(1,256
|
)
|
|
(3,346
|
)
|
||||
Stock- based compensation expense (1)
|
|
—
|
|
|
—
|
|
|
(1,664
|
)
|
|
(1,664
|
)
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Segment profit (loss)
|
|
$
|
(107
|
)
|
|
$
|
10
|
|
|
$
|
(2,920
|
)
|
|
$
|
(3,017
|
)
|
|
For the Three Months Ended October 31,
|
|||||||||||||||
|
2017
|
|
% of
Revenue
|
|
2016
|
|
% of
Revenue
|
|
%
Change
|
|||||||
Operating revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Personalized oncology solutions
|
$
|
378
|
|
|
7.3
|
%
|
|
$
|
497
|
|
|
11.2
|
%
|
|
(23.9
|
)%
|
Translational oncology solutions
|
4,825
|
|
|
92.7
|
|
|
3,960
|
|
|
88.8
|
|
|
21.8
|
%
|
||
|
|
|
|
|
|
|
|
|
|
|||||||
Total operating revenue
|
5,203
|
|
|
100.0
|
|
|
4,457
|
|
|
100.0
|
|
|
16.7
|
|
||
|
|
|
|
|
|
|
|
|
|
|||||||
Costs and operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Cost of personalized oncology solutions
|
259
|
|
|
5.0
|
|
|
374
|
|
|
8.4
|
|
|
(30.7
|
)
|
||
Cost of translational oncology solutions
|
2,394
|
|
|
46.0
|
|
|
1,829
|
|
|
41.0
|
|
|
30.9
|
|
||
Research and development
|
1,115
|
|
|
21.4
|
|
|
1,008
|
|
|
22.6
|
|
|
10.6
|
|
||
Sales and marketing
|
551
|
|
|
10.6
|
|
|
717
|
|
|
16.1
|
|
|
(23.2
|
)
|
||
General and administrative
|
954
|
|
|
18.3
|
|
|
1,022
|
|
|
22.9
|
|
|
(6.7
|
)
|
||
|
|
|
|
|
|
|
|
|
|
|||||||
Total costs and operating expenses
|
5,273
|
|
|
101.3
|
|
|
4,950
|
|
|
111.0
|
|
|
6.5
|
|
||
Loss from operations
|
$
|
(70
|
)
|
|
(1.3
|
)%
|
|
$
|
(493
|
)
|
|
(11.0
|
)%
|
|
(85.8
|
)%
|
101.INS*
|
|
XBRL Instance Document.
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document.
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
CHAMPIONS ONCOLOGY, INC.
|
|
|
(Registrant)
|
|
|
|
|
Date: December 15, 2017
|
By:
|
/s/ Ronnie Morris
|
|
|
Ronnie Morris
|
|
|
Chief Executive Officer
|
|
|
(principal executive officer)
|
|
|
|
Date: December 15, 2017
|
By:
|
/s/ David Miller
|
|
|
David Miller
|
|
|
Chief Financial Officer
|
|
|
(principal financial and accounting officer)
|
1 Year Champions Oncology Chart |
1 Month Champions Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions